MYOF has been reported to be upregulated in several types of cancer, including triple-negative breast cancer (TNBC) (11), B-cell lymphoma (BCL), lung cancer (LC), hepatocellular carcinoma (HCC) (10), clear cell renal cell carcinoma (CCRCC) (12), colorectal cancer (CRC) (13), and pancreatic adenocarcinoma (PAAD) (14–18), but is not expressed in most normal tissues (10, 19, 20). This evidence concerns the gene MYOF and pancreatic adenocarcinoma.